FDA panel to discuss revising BE approaches for critical dose drugs
This article was originally published in Scrip
Executive Summary
The US FDA's advisory committee for pharmaceutical science and clinical pharmacology is scheduled to hold a meeting on April 13th to hear presentations from the Office of Generic Drugs concerning two bioequivalence (BE) topics relevant to generic drug approval.